Advanced Cardiovascular Systems, Inc.

Abbott Cardiovascular Systems, Inc.

Access Closure, Inc.

Florencia Lim

Mikael Trollsas

Edwin Wang

Jeong Soo Lee

Andreas Mylonakis

Michael H Ngo

Chi Le Long

Syed Faiyaz Ahmed Hossainy

Andy H Uchida

Scott Robert Sershen

Kevin To

Timothy Owens

Anthony P Spizuoco

Jacky Au-Yeung

Fozan El-Nounou

Deborah L Kilpatrick

Jeffrey T Ellis

Stephen D Pacetti

Syed F A Hossainy

Bin Huang

Paul M Consigny

Thierry Glauser

Florian Ludwig

Srinivasan Sridharan

Irina Astafieva

Robert D Ainsworth

Barbara E Stamberg

Liangxuan Zhang

Mary Suh

Lothar W Kleiner

Yiwen Tang

Charles David Claude

Marc Mehrzad Jalisi

Debashis Dutta

Jinping Wan

Chris Feezor

Jon A Becker

Bozena Zofia Maslanka

Qing Lin

Bridget A Hurley

Fernando Gonzalez

Vincent Bavaro

Vidya J Nayak

David J Sherman

Joann Heberer

Syed Fa Hossainy

Alfredo G Bayot

Nadine Ding

Carolyn Voyles

Xinmin Xu

NianJiong Bei

Huong Chung

Cheryl Stiger

Christopher L Haig

Michael Huy Ngo

Mikael O Trollsas

Jie Hu

A sealant is provided for sealing a puncture through tissue that includes an elongate first section including a proximal end, a distal end, and a cross-section sized for delivery into a puncture through tissue, and a second section fused to and extending from the distal end of the first section. The first section may be formed from a freeze-dried hydrogel that expands when exposed to physiological fluid within a puncture. The second section may be formed from a solid mass of non-freeze-dried, non-crosslinked hydrogel precursors, the precursors remaining in an unreactive state until exposed to an aqueous physiological, whereupon the precursors undergo in-situ crosslinking with one another to provide an adhesive layer bonded to the first section. Apparatus and methods for delivering the sealant into a puncture through tissue are also provided.

Apparatus and methods for sealing a vascular puncture

A sealant for sealing a puncture through tissue includes a first section, e.g., formed from freeze-dried hydrogel, and a second section extending from the distal end. The second section may be formed from PEG-precursors including PEG-ester and PEG-amine, e.g., in an equivalent ratio of active group sites of PEG-ester/PEG-amine greater than one-to-one, e.g., such that excess esters may provide faster activation upon contact with physiological fluids and enhance adhesion of the sealant within a puncture. At least some of the precursors remain in an unreactive state until exposed to an aqueous physiological environment, e.g., within a puncture, whereupon the precursors undergo in-situ cross-linking to provide adhesion to tissue adjacent the puncture. For example, the PEG-amine precursors may include the free amine form and the salt form. The free amine form at least partially cross-links with the PEG-ester and the salt form remains in the unreactive state in the sealant before introduction into the puncture.

A sealant is provided for sealing a puncture through tissue that comprises an elongate first section including a proximal end, a distal end, and a cross-section sized for delivery into a puncture through tissue, and a second section extending from the distal end of the first section. The first section may be formed from a freeze-dried hydrogel that expands when exposed to physiological fluid within a puncture. The first section comprises chitosan and at least one additional polymer. The second section may be formed from a solid mass of non-freeze-dried, non-cross-linked hydrogel precursors. The precursors are in an unreactive state until exposed to an aqueous physiological environment, whereupon the precursors undergo in-situ crosslinking with one another to provide an adhesive layer bonded to the first section. The second section may further comprise chitosan. Apparatus and methods for delivering the sealant into a puncture through tissue are also provided.

Chitosan and polyethylene glycol copolymers and methods and devices for using same for sealing a vascular puncture

Devices and methods for treating a diseased tracheobronchial region in a mammal. The device can be a stent which can include a sustained-release material such as a polymer matrix with a treatment agent. The stent can be bioabsorbable and a treatment agent can be incorporated therewith. A treatment method can be delivery of a stent to a tracheobronchial region by a delivery device such as a catheter assembly.

Tracheobronchial implantable medical device and methods of use

The present invention provides a semi-crystalline polymer for a coating on an implantable device for controlling release of drug and methods of making and using the same.

Bioabsorbable semi-crystalline polymer for controlling release of drug from a coating

The present invention provides a coating comprising a reservoir layer comprising a semi-crystalline polymer and a primer layer comprising an amorphous polymer on an implantable device and methods of making and using the same.

Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer

The present invention provides an implantable article comprising an amorphous terpolymer and a semi-crystalline polymer. The amorphous terpolymer can be admixed with the semi-crystalline polymer or form a block copolymer with the semi-crystalline polymer.

Polymers comprising amorphous terpolymers and semicrystalline blocks

This invention is directed to methods of treating solid tumor cancers, particularly refractory cancers by administration of two pluralities of microparticles, one comprising drug-carrying microparticles sized to lodge at the tumor preferably in the capillary bed of the tumor and the other comprising non-drug-carrying microparticles sized to lodge in the arterial system servicing the tumor so as to embolize the tumor.

Method of treating malignant solid tumors using transcatheter arterial chemoembolization (TACE)

Growing community of inventors

Union City, CA, United States of America

Florencia Lim